Is Small Really Beautiful? Nanosensors and Low Abundance Biomarkers for Personalized Medicine

ISSN: 1875-6913 (Online)
ISSN: 1875-6921 (Print)

Volume 15, 2 Issues, 2017

Download PDF Flyer

Current Pharmacogenomics and Personalized Medicine

Formerly: Current Pharmacogenomics

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Submit Abstracts Online Submit Manuscripts Online

Adrián LLerena, MD, Ph.D
Extremadura University
Hospital and Medical School
Badajoz, Extremadura

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Is Small Really Beautiful? Nanosensors and Low Abundance Biomarkers for Personalized Medicine

Current Pharmacogenomics and Personalized Medicine, 11(4): 295-308.

Author(s): Noelia Dasilva, Ricardo Jara-Acevedo, Maria Gonzalez-Gonzalez, Alberto Orfao and Manuel Fuentes.

Affiliation: Departamento de Medicina& Servicio General Citometría, Centro de Investigación del Cáncer/IBMCC (USAL/CSIC), IBSAL, Campus Miguel de Unamuno s/n. 37007 Salamanca. Spain.


Biomarkers are defined as a characteristic that is objectively measured and evaluated as an indicator of normal biological or pathogenic processes or pharmacological responses to a therapeutic intervention. Over the past few decades, a growing interest in the identification of biomarkers has emerged in order to detect different pathologies in the early stages. Thus, it would be possible to provide a customized treatment to the patient, improving their outcome. Owing this purpose, proteomics has allowed the development of new methodologies and technologies which are able of detecting low-abundance proteins. This is due, in part, to the development of novel promising materials, such as quantum dots or silicon nanowires. Such emerging approaches come with the advantage of their high sensitivity, low-volume requirements or the potential high-throughput applications, among others. However, since huge information has been generated through nanoproteomic techniques, only few applications have arrived to the clinics. Referring to personalized medicine and targeted therapies, it has to be mentioned that the development of more specific drugs can be improved by the use of biomarkers, helping with decisions about dose, schedule and patient population. In this review, we summarize and highlight the utility of biomarkers identified through nanoproteomics for personalized medicine as well as the applications in the clinic and the future perspectives


Biomarker, cancer, clinics, nanosensors, nanotechnology, personalized medicine, proteomics, validation.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 11
Issue Number: 4
First Page: 295
Last Page: 308
Page Count: 14
DOI: 10.2174/1875692111666131211235022
Price: $58

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science